Todd Brady, Aldeyra Therapeutics CEO
July 12, 2022 09:35 AM EDTUpdated 10:34 AM
R&D

'Ap­prov­abil­i­ty has been put to bed': Aldeyra says eye drop clears three dry eye sig­nals en route to FDA

Kyle LaHucik

Senior Reporter

Aldeyra’s at­tempt at treat­ing dry eye dis­ease has seen a few ups and downs in re­cent years, but the biotech’s sight to ap­proval got a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

A service from the Financial Times